
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6865196/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Doubleâ€Blind, Placeboâ€Controlled, Crossover Study in Healthy Subjects. Clinical Pharmacology and Therapeutics, 2022, 111, 886-895.	2.3	70
2	Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology, 2022, 47, 1180-1187.	2.8	72
3	Premature aging in mice with error-prone protein synthesis. Science Advances, 2022, 8, eabl9051.	4.7	24
4	Phenotype of Mrps5-Associated Phylogenetic Polymorphisms Is Intimately Linked to Mitoribosomal Misreading. International Journal of Molecular Sciences, 2022, 23, 4384.	1.8	1
5	Rhodiola Rosea Extract Counteracts Stress in an Adaptogenic Response Curve Manner via Elimination of ROS and Induction of Neurite Outgrowth. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-19.	1.9	8
6	Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology, 2021, 46, 537-544.	2.8	120
7	Low Doses of LSD Acutely Increase BDNF Blood Plasma Levels in Healthy Volunteers. ACS Pharmacology and Translational Science, 2021, 4, 461-466.	2.5	71
8	Aerobic Exercise and Stretching as Add-On to Inpatient Treatment for Depression Have No Differential Effects on Stress-Axis Activity, Serum-BDNF, TNF-Alpha and Objective Sleep Measures. Brain Sciences, 2021, 11, 411.	1.1	12
9	Random errors in protein synthesis activate an age-dependent program of muscle atrophy in mice. Communications Biology, 2021, 4, 703.	2.0	8
10	Role of the 5-HT2A Receptor in Acute Effects of LSD on Empathy and Circulating Oxytocin. Frontiers in Pharmacology, 2021, 12, 711255.	1.6	30
11	Oxytocin levels in response to pituitary provocation tests in healthy volunteers. European Journal of Endocrinology, 2021, 185, 355-364.	1.9	5
12	Sex differences in Alzheimer's disease: metabolic reprogramming and therapeutic intervention. Trends in Endocrinology and Metabolism, 2021, 32, 963-979.	3.1	20
13	Silencing of the ER and Integrative Stress Responses in the Liver of Mice with Error-Prone Translation. Cells, 2021, 10, 2856.	1.8	2
14	Mitochondria modulatory effects of new TSPO ligands in a cellular model of tauopathies. Journal of Neuroendocrinology, 2020, 32, e12796.	1.2	22
15	Effect of trauma-informed care on hair cortisol concentration in youth welfare staff and client physical aggression towards staff: results of a longitudinal study. BMC Public Health, 2020, 20, 21.	1.2	27
16	Distinct acute effects of LSD, MDMA, and d-amphetamine in healthy subjects. Neuropsychopharmacology, 2020, 45, 462-471.	2.8	141
17	Dietary Mitophagy Enhancer: A Strategy for Healthy Brain Aging?. Antioxidants, 2020, 9, 932.	2.2	35
18	Indices of cortical plasticity after therapeutic sleep deprivation in patients with major depressive disorder. Journal of Affective Disorders, 2020, 277, 425-435.	2.0	12

#	Article	IF	CITATIONS
19	Modulating endothelial adhesion and migration impacts stem cell therapies efficacy. EBioMedicine, 2020, 60, 102987.	2.7	10
20	Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing. Nature Reviews Drug Discovery, 2020, 19, 609-633.	21.5	441
21	Clock-Controlled Mitochondrial Dynamics Correlates with Cyclic Pregnenolone Synthesis. Cells, 2020, 9, 2323.	1.8	9
22	Insights into Disease-Associated Tau Impact on Mitochondria. International Journal of Molecular Sciences, 2020, 21, 6344.	1.8	50
23	Honeybush Extracts (Cyclopia spp.) Rescue Mitochondrial Functions and Bioenergetics against Oxidative Injury. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-14.	1.9	10
24	Exploring the effectiveness of a specialized therapy programme for burnout using subjective report and biomarkers of stress. Clinical Psychology and Psychotherapy, 2020, 28, 852-861.	1.4	3
25	Influence of Regular Physical Activity on Mitochondrial Activity and Symptoms of Burnout—An Interventional Pilot Study. Journal of Clinical Medicine, 2020, 9, 667.	1.0	15
26	Hypothalamic-pituitary-adrenal axis activation in a high-risk sample of children, adolescents and young adults in residential youth care – Associations with adverse childhood experiences and mental health problems. Psychiatry Research, 2020, 284, 112778.	1.7	19
27	Management of mild cognitive impairment (MCI): The need for national and international guidelines. World Journal of Biological Psychiatry, 2020, 21, 579-594.	1.3	100
28	Plasma and serum brain-derived neurotrophic factor (BDNF) levels and their association with neurocognition in at-risk mental state, first episode psychosis and chronic schizophrenia patients. World Journal of Biological Psychiatry, 2019, 20, 545-554.	1.3	37
29	Repetitive enhancement of serum <scp>BDNF</scp> subsequent to continuation <scp>ECT</scp> . Acta Psychiatrica Scandinavica, 2019, 140, 426-434.	2.2	19
30	TSPO Ligands Boost Mitochondrial Function and Pregnenolone Synthesis. Journal of Alzheimer's Disease, 2019, 72, 1045-1058.	1.2	38
31	Link between the unfolded protein response and dysregulation of mitochondrial bioenergetics in Alzheimer's disease. Cellular and Molecular Life Sciences, 2019, 76, 1419-1431.	2.4	37
32	The impact of lifestyle Physical Activity Counselling in IN-PATients with major depressive disorders on physical activity, cardiorespiratory fitness, depression, and cardiovascular health risk markers: study protocol for a randomized controlled trial. Trials, 2019, 20, 367.	0.7	29
33	Mitochondria- and Oxidative Stress-Targeting Substances in Cognitive Decline-Related Disorders: From Molecular Mechanisms to Clinical Evidence. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-26.	1.9	77
34	Effects of Aerobic Exercise as Add-On Treatment for Inpatients With Moderate to Severe Depression on Depression Severity, Sleep, Cognition, Psychological Well-Being, and Biomarkers: Study Protocol, Description of Study Population, and Manipulation Check. Frontiers in Psychiatry, 2019, 10, 262.	1.3	15
35	Acute and subsequent continuation electroconvulsive therapy elevates serum BDNF levels in patients with major depression. Brain Stimulation, 2019, 12, 1041-1050.	0.7	30
36	Brain-derived neurotrophic factor as a biomarker of insomnia. European Neuropsychopharmacology, 2019, 29, S514-S515.	0.3	0

#	Article	IF	CITATIONS
37	Ginkgo biloba extract increases neurite outgrowth and activates the Akt/mTOR pathway. PLoS ONE, 2019, 14, e0225761.	1.1	16
38	Brain-derived neurotrophic factor is a biomarker for subjective insomnia but not objectively assessable poor sleep continuity. Journal of Psychiatric Research, 2019, 110, 103-109.	1.5	34
39	Therapeutic efficacy of the Ginkgo special extract EGb761 [®] within the framework of the mitochondrial cascade hypothesis of Alzheimer's disease. World Journal of Biological Psychiatry, 2019, 20, 173-189.	1.3	45
40	Ginkgo biloba extract increases neurite outgrowth and activates the Akt/mTOR pathway. , 2019, 14, e0225761.		0
41	Ginkgo biloba extract increases neurite outgrowth and activates the Akt/mTOR pathway. , 2019, 14, e0225761.		0
42	Ginkgo biloba extract increases neurite outgrowth and activates the Akt/mTOR pathway. , 2019, 14, e0225761.		0
43	Ginkgo biloba extract increases neurite outgrowth and activates the Akt/mTOR pathway. , 2019, 14, e0225761.		0
44	Circadian Control of DRP1 Activity Regulates Mitochondrial Dynamics and Bioenergetics. Cell Metabolism, 2018, 27, 657-666.e5.	7.2	186
45	Mutant <scp>MRPS</scp> 5 affects mitoribosomal accuracy and confers stressâ€related behavioral alterations. EMBO Reports, 2018, 19, .	2.0	26
46	Neuronal Mitochondrial Dysfunction Activates the Integrated Stress Response to Induce Fibroblast Growth Factor 21. Cell Reports, 2018, 24, 1407-1414.	2.9	72
47	Mitochondria, Estrogen and Female Brain Aging. Frontiers in Aging Neuroscience, 2018, 10, 124.	1.7	65
48	Brain aging and neurodegeneration: from a mitochondrial point of view. Journal of Neurochemistry, 2017, 143, 418-431.	2.1	402
49	Allopregnanolone and its analog BR 297 rescue neuronal cells from oxidative stress-induced death through bioenergetic improvement. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2017, 1863, 631-642.	1.8	30
50	Discovery of Imidazoquinazolinone Derivatives as TSPO Ligands Modulating Neurosteroidogenesis and Cellular Bioenergetics in Neuroblastoma Cells Expressing Amyloid Precursor Protein. ChemistrySelect, 2017, 2, 6452-6457.	0.7	9
51	Genetic ablation of the p66Shc adaptor protein reverses cognitive deficits and improves mitochondrial function in an APP transgenic mouse model of Alzheimer's disease. Molecular Psychiatry, 2017, 22, 605-614.	4.1	26
52	Amyloid-β–Induced Changes in Molecular Clock Properties and Cellular Bioenergetics. Frontiers in Neuroscience, 2017, 11, 124.	1.4	19
53	Psychopharmakotherapie – pharmakologische Grundlagen. , 2017, , 749-793.		2
54	Alzheimer's amyloid-β peptide disturbs P2X7 receptor-mediated circadian oscillations of intracellular calcium. Folia Neuropathologica, 2016, 4, 360-368.	0.5	11

#	Article	IF	CITATIONS
55	Non-24-Hour Sleep-Wake Disorder Revisited – A Case Study. Frontiers in Neurology, 2016, 7, 17.	1.1	15
56	Increased superior frontal gyrus activation during working memory processing in psychosis: Significant relation to cumulative antipsychotic medication and to negative symptoms. Schizophrenia Research, 2016, 175, 20-26.	1.1	15
57	Alzheimer, mitochondria and gender. Neuroscience and Biobehavioral Reviews, 2016, 67, 89-101.	2.9	85
58	Tau physiology and pathomechanisms in frontotemporal lobar degeneration. Journal of Neurochemistry, 2016, 138, 71-94.	2.1	85
59	Mature brain-derived neurotrophic factor (BDNF) is the major player of total BDNF in serum regarding prediction of antidepressant treatment outcome. Psychopharmacology, 2016, 233, 153-155.	1.5	6
60	BDNF in sleep, insomnia, and sleep deprivation. Annals of Medicine, 2016, 48, 42-51.	1.5	190
61	Role of Serum Brain Derived Neurotrophic Factor and Central N-Acetylaspartate for Clinical Response under Antidepressive Pharmacotherapy. NeuroSignals, 2016, 24, 1-14.	0.5	18
62	Advanced Mitochondrial Respiration Assay for Evaluation of Mitochondrial Dysfunction in Alzheimer's Disease. Methods in Molecular Biology, 2016, 1303, 171-183.	0.4	6
63	Mitochondrial dysfunction: the missing link between aging and sporadic Alzheimer's disease. Biogerontology, 2016, 17, 281-296.	2.0	149
64	Synaptic dysfunction, memory deficits and hippocampal atrophy due to ablation of mitochondrial fission in adult forebrain neurons. Cell Death and Differentiation, 2016, 23, 18-28.	5.0	94
65	Sex hormone-related neurosteroids differentially rescue bioenergetic deficits induced by amyloid-β or hyperphosphorylated tau protein. Cellular and Molecular Life Sciences, 2016, 73, 201-215.	2.4	79
66	P1-079: Sex hormone-related neurosteroids differentially rescue bioenergetic deficits induced by amyloid-β or hyperphosphorylated tau protein. , 2015, 11, P368-P368.		0
67	Hippocampal volume and functional connectivity changes during the female menstrual cycle. NeuroImage, 2015, 118, 154-162.	2.1	151
68	Improved Alertness Is Associated with Early Increase in Serum Brain-Derived Neurotrophic Factor and Antidepressant Treatment Outcome in Major Depression. Neuropsychobiology, 2015, 72, 16-28.	0.9	20
69	BDNF: an indicator of insomnia?. Molecular Psychiatry, 2014, 19, 151-152.	4.1	92
70	Improvement of neuronal bioenergetics by neurosteroids: Implications for age-related neurodegenerative disorders. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 2427-2438.	1.8	84
71	Gamma-hydroxybutyrate, acting through an anti-apoptotic mechanism, protects native and amyloid-precursor-protein-transfected neuroblastoma cells against oxidative stress-induced death. Neuroscience, 2014, 263, 203-215.	1.1	20
72	High baseline BDNF serum levels and early psychopathological improvement are predictive of treatment outcome in major depression. Psychopharmacology, 2014, 231, 2955-2965.	1.5	56

#	Article	IF	CITATIONS
73	Fast BDNF serum level increase and diurnal BDNF oscillations are associated with therapeutic response after partial sleep deprivation. Journal of Psychiatric Research, 2014, 59, 1-7.	1.5	62
74	March separate, strike together — Role of phosphorylated TAU in mitochondrial dysfunction in Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 1258-1266.	1.8	92
75	Calcium channel blockers and dementia. British Journal of Pharmacology, 2013, 169, 1203-1210.	2.7	115
76	Lessons from two prevalent amyloidoses—what amylin and Aβ have in common. Frontiers in Aging Neuroscience, 2013, 5, 38.	1.7	36
77	The Interplay of Stress and Sleep Impacts BDNF Level. PLoS ONE, 2013, 8, e76050.	1.1	84
78	Alzheimer's disease models and functional genomics—How many needles are there in the haystack?. Frontiers in Physiology, 2012, 3, 320.	1.3	18
79	Early accumulation of intracellular fibrillar oligomers and late congophilic amyloid angiopathy in mice expressing the Osaka intra-Al² APP mutation. Translational Psychiatry, 2012, 2, e183-e183.	2.4	45
80	Mitochondrial effects of <i>Ginkgo biloba extract</i> . International Psychogeriatrics, 2012, 24, S18-S20.	0.6	30
81	Transfection of Human Neuroblastoma Cells with AlzheimerÂ's Disease Brain Hallmarks as a Promising Strategy to Investigate the Role of Neurosteroidogenesis in Neuroprotection. BioValley Monographs, 2012, , 50-59.	0.1	4
82	Role of hippocalcin in mediating AÎ ² toxicity. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2012, 1822, 1247-1257.	1.8	12
83	Insights into Mitochondrial Dysfunction: Aging, Amyloid-β, and Tau–A Deleterious Trio. Antioxidants and Redox Signaling, 2012, 16, 1456-1466.	2.5	115
84	Alzheimer's Disease, Oestrogen and Mitochondria: an Ambiguous Relationship. Molecular Neurobiology, 2012, 46, 151-160.	1.9	51
85	A New Link to Mitochondrial Impairment in Tauopathies. Molecular Neurobiology, 2012, 46, 205-216.	1.9	109
86	Peripheral Mitochondrial Dysfunction in Alzheimer's Disease: Focus on Lymphocytes. Molecular Neurobiology, 2012, 46, 194-204.	1.9	107
87	Mitochondrial dysfunction - the beginning of the end in Alzheimer's disease? Separate and synergistic modes of tau and amyloid-l² toxicity. Alzheimer's Research and Therapy, 2011, 3, 15.	3.0	136
88	Combined expression of tau and the Harlequin mouse mutation leads to increased mitochondrial dysfunction, tau pathology and neurodegeneration. Neurobiology of Aging, 2011, 32, 1827-1838.	1.5	27
89	Amyloid-Beta Interaction with Mitochondria. International Journal of Alzheimer's Disease, 2011, 2011, 1-12.	1.1	219
90	Inhibition of the Mitochondrial Enzyme ABAD Restores the Amyloid-Î ² -Mediated Deregulation of Estradiol. PLoS ONE, 2011, 6, e28887.	1.1	49

#	Article	IF	CITATIONS
91	Lipoxygenases and Poly(ADP-Ribose) Polymerase in Amyloid Beta Cytotoxicity. Neurochemical Research, 2011, 36, 839-848.	1.6	16
92	Modes of Aβ toxicity in Alzheimer's disease. Cellular and Molecular Life Sciences, 2011, 68, 3359-3375.	2.4	78
93	Serum factors in older individuals change cellular clock properties. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 7218-7223.	3.3	84
94	Pilot study of the application of magnetic bead protein profiling to the study of biomarkers in addiction research. World Journal of Biological Psychiatry, 2011, 12, 80-84.	1.3	3
95	Aging and Circadian Disruption: Causes and Effects. Aging, 2011, 3, 813-817.	1.4	45
96	Psychopharmakotherapie: pharmakologische Grundlagen. , 2011, , 683-729.		0
97	Convergence of Amyloid-β and Tau Pathologies on Mitochondria In Vivo. Molecular Neurobiology, 2010, 41, 107-114.	1.9	144
98	Mitochondrial Dysfunction: Common Final Pathway in Brain Aging and Alzheimer's Disease—Therapeutic Aspects. Molecular Neurobiology, 2010, 41, 159-171.	1.9	222
99	Sciatic nerve injury induces apoptosis of dorsal root ganglion satellite glial cells and selectively modifies neurosteroidogenesis in sensory neurons. Glia, 2010, 58, 169-180.	2.5	57
100	Aβ and human amylin share a common toxicity pathway <i>via</i> mitochondrial dysfunction. Proteomics, 2010, 10, 1621-1633.	1.3	112
101	The metabolic enhancer piracetam ameliorates the impairment of mitochondrial function and neurite outgrowth induced by ĀŸâ€amyloid peptide. British Journal of Pharmacology, 2010, 160, 246-257.	2.7	42
102	The Physiological Period Length of the Human Circadian Clock In Vivo Is Directly Proportional to Period in Human Fibroblasts. PLoS ONE, 2010, 5, e13376.	1.1	76
103	Dissecting Toxicity of Tau and Î ² -Amyloid. Neurodegenerative Diseases, 2010, 7, 10-12.	0.8	25
104	Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models. Cell, 2010, 142, 387-397.	13.5	1,563
105	Ginkgo Biloba Extract Ameliorates Oxidative Phosphorylation Performance and Rescues AÎ ² -Induced Failure. PLoS ONE, 2010, 5, e12359.	1.1	62
106	Amyloid-β and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 20057-20062.	3.3	581
107	Amyloid-beta Leads to Impaired Cellular Respiration, Energy Production and Mitochondrial Electron Chain Complex Activities in Human Neuroblastoma Cells. Cellular and Molecular Neurobiology, 2009, 29, 1063-1071.	1.7	172
108	Survival, neuron-like differentiation and functionality of mesenchymal stem cells in neurotoxic environment: the critical role of erythropoietin. Cell Death and Differentiation, 2009, 16, 1599-1614.	5.0	56

#	Article	IF	CITATIONS
109	Mitochondrial dysfunction: An early event in Alzheimer pathology accumulates with age in AD transgenic mice. Neurobiology of Aging, 2009, 30, 1574-1586.	1.5	395
110	Oligomeric and fibrillar species of β-amyloid (Aβ42) both impair mitochondrial function in P301L tau transgenic mice. Journal of Molecular Medicine, 2008, 86, 1255-1267.	1.7	123
111	Dose-dependent and sequence-sensitive effects of amyloid-β peptide on neurosteroidogenesis in human neuroblastoma cells. Neurochemistry International, 2008, 52, 948-955.	1.9	38
112	Selective regulation of neurosteroid biosynthesis in human neuroblastoma cells under hydrogen peroxide–induced oxidative stress condition. Neuroscience, 2008, 151, 758-770.	1.1	23
113	Soluble Beta-Amyloid Leads to Mitochondrial Defects in Amyloid Precursor Protein and Tau Transgenic Mice. Neurodegenerative Diseases, 2008, 5, 157-159.	0.8	134
114	Psychopharmakotherapie â \in " Pharmakologische Grundlagen. , 2008, , 583-623.		0
115	The MT2 Melatonin Receptor Subtype is Present in Human Retina and Decreases in Alzheimers Disease. Current Alzheimer Research, 2007, 4, 47-51.	0.7	66
116	Enhanced apoptosis, oxidative stress and mitochondrial dysfunction in lymphocytes as potential biomarkers for Alzheimer's disease. , 2007, , 207-215.		57
117	Mitochondrial Dysfunction: The First Domino in Brain Aging and Alzheimer's Disease?. Antioxidants and Redox Signaling, 2007, 9, 1659-1676.	2.5	182
118	Stabilization of mitochondrial function by Ginkgo biloba extract (EGb 761). Pharmacological Research, 2007, 56, 493-502.	3.1	144
119	Effects of Alzheimer's amyloid-beta and tau protein on mitochondrial function—role of glucose metabolism and insulin signalling. Archives of Physiology and Biochemistry, 2007, 113, 131-141.	1.0	46
120	Inverse and distinct modulation of tau-dependent neurodegeneration by presenilin 1 and amyloid-? in cultured cortical neurons: evidence that tau phosphorylation is the limiting factor in amyloid-? in amyloid-? induced cell death. Journal of Neurochemistry, 2007, 101, 1303-1315.	2.1	60
121	The amyloid precursor protein potentiates CHOP induction and cell death in response to ER Ca2+ depletion. Biochimica Et Biophysica Acta - Molecular Cell Research, 2007, 1773, 157-165.	1.9	39
122	Increased T-cell Reactivity and Elevated Levels of CD8+ Memory T-cells in Alzheimer's Disease-patients and T-cell Hyporeactivity in an Alzheimer's Disease-mouse Model: Implications for Immunotherapy. NeuroMolecular Medicine, 2007, 9, 340-354.	1.8	42
123	Nitric oxide alters arachidonic acid turnover in brain cortex synaptoneurosomes. Neurochemistry International, 2006, 48, 1-8.	1.9	24
124	Mitochondrial dysfunction induced by disease relevant AβPP and tau protein mutations. Journal of Alzheimer's Disease, 2006, 9, 139-146.	1.2	33
125	Oxidative Stress and Neurodegenerative Disease. , 2006, , 627-647.		1
126	Piracetam improves mitochondrial dysfunction following oxidative stress. British Journal of Pharmacology, 2006, 147, 199-208.	2.7	79

#	Article	IF	CITATIONS
127	Apolipoprotein E epsilon 4 is associated with an increased vulnerability to cell death in Alzheimer's disease. Journal of Neural Transmission, 2006, 113, 1753-1761.	1.4	17
128	Aging sensitizes toward ROS formation and lipid peroxidation in PS1M146L transgenic mice. Free Radical Biology and Medicine, 2006, 40, 850-862.	1.3	87
129	Mitochondrial dysfunction in sporadic and genetic Alzheimer's disease. Experimental Gerontology, 2006, 41, 668-673.	1.2	112
130	Modulation of neurosteroid production in human neuroblastoma cells by Alzheimer's disease key proteins. Journal of Neurobiology, 2006, 66, 868-881.	3.7	40
131	Apoptosis of CD4+ T and Natural Killer Cells in Alzheimer's Disease. Pharmacopsychiatry, 2006, 39, 220-228.	1.7	41
132	Pineal and cortical melatonin receptors MT1 and MT2 are decreased in Alzheimer's disease. European Journal of Histochemistry, 2006, 50, 311-6.	0.6	71
133	Stabilization of Mitochondrial Membrane Potential and Improvement of Neuronal Energy Metabolism by Ginkgo Biloba Extract EGb 761. Annals of the New York Academy of Sciences, 2005, 1056, 474-485.	1.8	109
134	Reduced hippocampal MT2 melatonin receptor expression in Alzheimer's disease. Journal of Pineal Research, 2005, 38, 10-16.	3.4	187
135	Enhanced ROS-Generation in Lymphocytes from Alzheimer's Patients. Pharmacopsychiatry, 2005, 38, 312-315.	1.7	47
136	Proteomic and Functional Analyses Reveal a Mitochondrial Dysfunction in P301L Tau Transgenic Mice. Journal of Biological Chemistry, 2005, 280, 23802-23814.	1.6	362
137	Impaired Cu/Zn-SOD activity contributes to increased oxidative damage in APP transgenic mice. Neurobiology of Disease, 2005, 18, 89-99.	2.1	143
138	Amyloid β-induced Changes in Nitric Oxide Production and Mitochondrial Activity Lead to Apoptosis. Journal of Biological Chemistry, 2004, 279, 50310-50320.	1.6	261
139	Impact of gender on upregulation of antioxidant defence mechanisms in Alzheimer?s disease brain. Journal of Neural Transmission, 2004, 111, 1167-82.	1.4	79
140	Age-related alteration of activity and gene expression of endothelial nitric oxide synthase in different parts of the brain in rats. Neuroscience Letters, 2004, 370, 175-179.	1.0	20
141	Impact of Aging: Sporadic, and Genetic Risk Factors on Vulnerability to Apoptosis in Alzheimer's Disease. NeuroMolecular Medicine, 2003, 4, 161-178.	1.8	30
142	Increased Apoptotic Cell Death in Sporadic and Genetic Alzheimer's Disease. Annals of the New York Academy of Sciences, 2003, 1010, 604-609.	1.8	76
143	Mitochondrial dysfunction, apoptotic cell death, and Alzheimer's disease. Biochemical Pharmacology, 2003, 66, 1627-1634.	2.0	280
144	The amyloid precursor protein protects PC12 cells against endoplasmic reticulum stress-induced apoptosis. Journal of Neurochemistry, 2003, 87, 248-256.	2.1	57

#	Article	IF	CITATIONS
145	Neurotoxic Mechanisms Caused by the Alzheimer's Disease-linked Swedish Amyloid Precursor Protein Mutation. Journal of Biological Chemistry, 2003, 278, 28294-28302.	1.6	154
146	Dietary Cu stabilizes brain superoxide dismutase 1 activity and reduces amyloid AÂ production in APP23 transgenic mice. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 14187-14192.	3.3	330
147	Effects of EGb 761® Ginkgo biloba Extract on Mitochondrial Function and Oxidative Stress. Pharmacopsychiatry Supplement, 2003, 36, 15-23.	0.8	99
148	Psychopharmakotherapie: pharmakologische Grundlagen. , 2003, , 513-564.		1
149	Age-related impairment of human T lymphocytes' activation: specific differences between CD4+ and CD8+ subsets. Mechanisms of Ageing and Development, 2002, 123, 375-390.	2.2	69
150	Reduction of Trophic Support Enhances Apoptosis in PC12 Cells Expressing Alzheimer's APP Mutation and Sensitizes Cells to Staurosporine-Induced Cell Death. Journal of Molecular Neuroscience, 2002, 18, 189-202.	1.1	22
151	Alzheimer's Disease-like Alterations in Peripheral Cells from Presenilin-1 Transgenic Mice. Neurobiology of Disease, 2001, 8, 331-342.	2.1	55
152	Elevated Levels of Fragmented DNA Nucleosomes in Native and Activated Lymphocytes Indicate an Enhanced Sensitivity to Apoptosis in Sporadic Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2001, 12, 98-105.	0.7	29
153	ROS generation, lipid peroxidation and antioxidant enzyme activities in the aging brain. Journal of Neural Transmission, 2001, 108, 955-967.	1.4	175
154	Age-related increase of oxidative stress-induced apoptosis in micePrevention by Ginkgo biloba extract (EGb761). Journal of Neural Transmission, 2001, 108, 969-978.	1.4	81
155	Elevated vulnerability to oxidative stress-induced cell death and activation of caspase-3 by the Swedish amyloid precursor protein mutation. Journal of Neuroscience Research, 2001, 64, 183-192.	1.3	91
156	Acute Stress Induced Modifications of Calcium Signaling in Learned Helpless Rats. Pharmacopsychiatry, 2000, 33, 132-137.	1.7	13
157	Reduced antioxidant enzyme activity in brains of mice transgenic for human presenilin-1 with single or multiple mutations. Neuroscience Letters, 2000, 292, 87-90.	1.0	59
158	Age-related changes of apoptotic cell death in human lymphocytes. Neurobiology of Aging, 2000, 21, 661-670.	1.5	66
159	Piracetam: Novelty in a Unique Mode of Action. Pharmacopsychiatry, 1999, 32, 2-9.	1.7	74
160	Enhanced vulnerability to apoptotic cell death in sporadic Alzheimer's disease. NeuroReport, 1998, 9, 2443-2446.	0.6	16
161	Changes of intracellular calcium regulation in Alzheimer's disease and vascular dementia. Journal of Neural Transmission Supplementum, 1998, 54, 201-210.	0.5	5
162	Lymphocytes as cell model to study apoptosis in Alzheimer's disease: vulnerability to programmed cell death appears to be altered. Journal of Neural Transmission Supplementum, 1998, 54, 259-267.	0.5	42

#	Article	IF	CITATIONS
163	Free Intracellular Calcium in Peripheral Cells in Alzheimer's Disease. Neurobiology of Aging, 1997, 18, 281-284.	1.5	24
164	The Amplifying Effect of β-Amyloid on Cellular Calcium Signalling in Alzheimer's Disease. , 1997, 167, 123-127.		0
165	Impaired Calcium Regulation in Subcortical Vascular Encephalopathy. Stroke, 1997, 28, 1351-1356.	1.0	5
166	Region-specific downregulation of free intracellular calcium in the aged rat brain. Neurobiology of Aging, 1996, 17, 557-563.	1.5	33
167	Free Intracellular Calcium in Aging and Alzheimer's Disease. Annals of the New York Academy of Sciences, 1996, 786, 305-320.	1.8	16
168	Down-regulation of free intracellular calcium in dissociated brain cells of aged mice and rats. Life Sciences, 1996, 59, 435-449.	2.0	22
169	Lymphocytes and neutrophils as peripheral models to study the effect of β-amyloid on cellular calcium signalling in Alzheimer's disease. Life Sciences, 1996, 59, 499-510.	2.0	20
170	β-amyloid amplifies PLC activity and Ca ²⁺ signalling in fully differentiated brain cells of adult mice. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 1996, 3, 234-241.	1.4	6
171	Vergleichbare altersabhägige Veräderungen der intrazelluläen Ca2+-Regulation in Maus, Ratte und Mensch. , 1996, , 783-786.		0
172	Reduktion des Ca2+-amplifizierenden Effektes von β-Amyloid an Lymphozyten von Alzheimer-Patienten — Möglicher Bezug zum Apolipoprotein E Polymorphismus. , 1996, , 787-792.		0
173	The amplifying effect of β-amyloid on cellular calcium signalling is reduced in Alzheimer's disease. NeuroReport, 1995, 6, 1199-1202.	0.6	19
174	β-amyloid peptide decreases membrane fluidity. Brain Research, 1995, 674, 133-136.	1.1	127
175	Similar age-related changes of free intracellular calcium in lymphocytes and central neurons: Effects of Alzheimer's disease. European Archives of Psychiatry and Clinical Neuroscience, 1994, 243, 218-223.	1.8	25
176	Platelet and lymphocyte free intracellular calcium in affective disorders. European Archives of Psychiatry and Clinical Neuroscience, 1994, 243, 235-239.	1.8	30
177	Apolipoprotein E and Cholesterol Affect Neuronal Calcium Signaling: The Possible Relationship to β-Amyloid Neurotoxicity. Biochemical and Biophysical Research Communications, 1994, 200, 1185-1192.	1.0	102
178	Disturbances of the neuronal calcium homeostasis in the aging nervous system. Life Sciences, 1994, 55, 2011-2018.	2.0	55
179	Alterations of intracellular calcium regulation during aging and Alzheimer's disease in nonneuronal cells. Life Sciences, 1994, 55, 2019-2029.	2.0	30

180 Free Intracellular Calcium in Aging and Alzheimer's Disease. , 1994, , 299-303.

1

#	Article	IF	CITATIONS
181	β-Amyloid protein enhances the mitogen-induced calcium response in circulating human lymphocytes. FEBS Letters, 1993, 330, 49-52.	1.3	39
182	β-Amyloid Protein Amplifies Calcium Signaling in Central Neurons from the Adult Mouse. Biochemical and Biophysical Research Communications, 1993, 194, 1216-1220.	1.0	67
183	Aging enhances the calcium sensitivity of central neurons of the mouse as an adaptive response to reduced free intracellular calcium. Neuroscience Letters, 1993, 152, 181-184.	1.0	23
184	Decreased β-amyloid sensitivity in Alzheimer's disease. Lancet, The, 1993, 342, 805-806.	6.3	31
185	Elevated intracellular calcium levels after 5-HT2 receptor stimulation in platelets of depressed patients. Biological Psychiatry, 1993, 34, 565-568.	0.7	63
186	Elevated intracellular calcium levels after 5-HT2 receptor stimulation in platelets of patients with affective disorders. European Neuropsychopharmacology, 1992, 2, 291-292.	0.3	1
187	Effects of 3,4-Methylenedioxymethamphetamine on Conditioned Fear Extinction and Retention in a Crossover Study in Healthy Subjects. Frontiers in Pharmacology, 0, 13, .	1.6	12